BACKGROUND: Data on the burden associated with schizophrenia relapse within the new treatment landscape is scarce. This study aims to identify relapse in schizophrenia and update their as...
This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida.
Background: There is limited literature on treatment patterns, healthcare resourc...
Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...
Background
Schizophrenia (SCZ) likely leads to changes in and/or loss of employment, which can result in changes to insurance coverage or “churn”. Since patients with schizophrenia are ty...
Objectives: Investigate demographic, clinical, and economic factors associated with treatment initiation of paliperidone palmitate (PP) and aripiprazole LAI (ALAI) in Medicaid patients wi...
Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...
Abstract: BACKGROUND: Quality measures were compared between patients initiated on second-generation long-acting injectable antipsychotics (SGLAIs) and oral atypical antipsychotics (OAAs)...
Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...
Background
Schizophrenia (SCZ) is most likely to develop in young adulthood. Using data from a single state, we describe the demographic and clinical characteristics of young adults in t...
BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...